Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Tumor Suppressor and Targeted Therapy in Hepatocellular Carcinoma: From Diagnosis...
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Tumor Suppressor and Targeted Therapy in Hepatocellular Carcinoma: From Diagnosis to Treatment (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 30 August 2026 | Viewed by 282

Special Issue Editors

Prof. Dr. Ching-Sheng Hsu

E-Mail Website
Guest Editor
1. Center for Digestive Medicine, Department of Medical Research, Taichung Tzu Chi Hospital, Taichung, Taiwan
2. School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan
Interests: liver cancer; viral hepatitis; fatty liver; liver cirrhosis
Special Issues, Collections and Topics in MDPI journals
Dr. Po-Heng Chuang

E-Mail Website
Guest Editor
Department of Gastroenterology, Division of Internal Medicine, Jen-Ai Hospital, Taichung 412224, Taiwan
Interests: hepatology; liver cancer; liver tumor biopsy and ablation; contrast ultrasound
Special Issues, Collections and Topics in MDPI journals
Dr. I-Cheng Lee

E-Mail Website
Guest Editor
National Yang-Ming University Taiwan, Taipei, Taiwan
Interests: cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to present this Special Issue, which is the second edition of a previous Special Issue on the topic of “Tumor Suppressor and Targeted Therapy in Hepatocellular Carcinoma: From Diagnosis to Treatment”. The carcinogenesis of HCC is a complex process that is associated with the aberrant activation of various cellular and molecular pathways and the disruption of the balance between the activation and inactivation of protooncogenes and tumor suppressor genes. In recent decades, advancements in molecular cell biology have improved our understanding of the detailed molecular mechanisms underlying tumor initiation and progression‚ contributing to the evolution of strategies for prevention, surveillance, early diagnosis, and treatment. Presently, many clinical trials that examine the use of molecular-targeted therapies that inhibit the growth of tumor cells by interfering with the molecular mechanisms of HCC carcinogenesis have generated promising results. In this Special Issue of Cancers, we aim to collate original and review articles concerning “tumor suppressor” or “targeted therapy” in hepatocellular carcinoma. The Editor and Co-Editors will select the highest-quality articles focused on topics such as clinical screening, genetic testing, diagnosis, treatments, and the prevention of complications in patients with hepatocellular carcinoma.

Prof. Dr. Ching-Sheng Hsu
Dr. Po-Heng Chuang
Dr. I-Cheng Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor suppressor
  • targeted therapy
  • hepatocellular carcinoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 2074 KB  
Article
Is There a Role for Hepatobiliary Scintigraphy in Thermal Ablation of Hepatocellular Carcinoma?
by Niek Wijnen, Joep de Bruijne, Rutger C. G. Bruijnen, Emma Ruijs, Hugo W. A. M. de Jong, Marnix G. E. H. Lam and Maarten L. J. Smits
Cancers 2026, 18(2), 322; https://doi.org/10.3390/cancers18020322 - 20 Jan 2026
Viewed by 121
Abstract
Purpose: Hepatobiliary scintigraphy (HBS) provides quantitative assessment of (future remnant) liver function, aiding clinical decision-making for surgical resection and radioembolization of hepatocellular carcinoma (HCC). However, its role for thermal ablation remains unexplored. This pilot study aimed to explore the potential role of [...] Read more.
Purpose: Hepatobiliary scintigraphy (HBS) provides quantitative assessment of (future remnant) liver function, aiding clinical decision-making for surgical resection and radioembolization of hepatocellular carcinoma (HCC). However, its role for thermal ablation remains unexplored. This pilot study aimed to explore the potential role of HBS in guiding patient selection and risk stratification for thermal ablation. Methods: All HCC patients who underwent thermal ablation between January 2021 and August 2025 and had HBS performed prior to ablation were retrospectively reviewed. Ablated non-tumor liver volumes (i.e., volume of ablated healthy parenchyma) were quantified using 3D segmentation. Absolute ablated liver function (i.e., the proportion of total HBS-derived liver function ablated) was also assessed. Clinical outcomes included changes in clinical scores (e.g., Child–Pugh) and the occurrence of hepatic decompensation after ablation. Results: Nine patients (13 tumors) were included. Median global HBS-derived liver function was 3.2%/min/m2 (range 1.6–6.8%/min/m2). Three patients developed hepatic decompensation > 3 months after ablation, unlikely related to thermal ablation itself. The patient with the lowest baseline function (1.6%/min/m2) tolerated ablation without hepatic decompensation. Median ablated non-tumor liver volume was 14.4 cm3 (range 3.1–46.7 cm3), corresponding to a median of 0.9% (range 0.2–3.6%) of total liver volume ablated per lesion. Median absolute ablated function was 0.05%/min/m2 (range 0.02–0.21%/min/m2). Conclusions: Thermal ablation was feasible and well tolerated even in patients with severely impaired liver function. Routine pre-ablation HBS does not appear necessary for thermal ablation of HCC, as only a small percentage of total functional liver volume is ablated. Full article
(This article belongs to the Special Issue Tumor Suppressor and Targeted Therapy in Hepatocellular Carcinoma: From Diagnosis to Treatment (2nd Edition))
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 644 KB  
Review
Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma
by Maanya Vittal, Bruna Menegassi and Manlio Vinciguerra
Cancers 2026, 18(3), 458; https://doi.org/10.3390/cancers18030458 - 30 Jan 2026
Abstract
Fenugreek (Trigonella foenum-graecum) has attracted growing interest as a complementary agent in the management of hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality worldwide. Its rich botanical and phytochemical profile, including key bioactive compounds such as diosgenin, trigonelline, saponins, and [...] Read more.
Fenugreek (Trigonella foenum-graecum) has attracted growing interest as a complementary agent in the management of hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality worldwide. Its rich botanical and phytochemical profile, including key bioactive compounds such as diosgenin, trigonelline, saponins, and flavonoids, underpins a spectrum of biological activities relevant to liver cancer therapy. This review critically examines the risks, benefits, and molecular targets of fenugreek administration in HCC, synthesising current evidence on extraction methods, standardisation, pharmacokinetics, and mechanisms of action. Preclinical studies highlight fenugreek’s antitumor efficacy, mediated by apoptosis induction, cell cycle regulation, and modulation of oxidative stress and inflammatory pathways, while its hepatoprotective effects are supported by robust antioxidant and anti-inflammatory properties. However, the safety profile is nuanced, with potential risks including reproductive toxicity, rare hypersensitivity reactions, and herb–drug interactions, particularly in patients with compromised hepatic function or polypharmacy. The review identifies critical gaps in clinical evidence, especially regarding long-term safety and synergistic effects with conventional therapies and underscores the need for rigorous standardisation and patient monitoring. We describe the potential integration of fenugreek into multimodal HCC treatment strategies, if safety concerns are addressed. Future research should elucidate precise molecular targets, optimise formulations, and conduct well-controlled clinical trials to fully realise fenugreek’s therapeutic potential in HCC management. Full article
(This article belongs to the Special Issue Tumor Suppressor and Targeted Therapy in Hepatocellular Carcinoma: From Diagnosis to Treatment (2nd Edition))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop